ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)

BACKGROUND: Approximately 50% of nGBMs harbor EGFR-amp. Depatuxizumab mafodotin (depatux-m) is an antibody drug conjugate: a monoclonal antibody that binds activated EGFR (wild-type and EGFRvIII mutant) linked to a microtubule-inhibitor toxin. Pre-clinical and earlier clinical trials suggested effic...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Lassman, Andrew, Pugh, Stephanie, Wang, Tony, Aldape, Kenneth, Gan, Hui, Preusser, Matthias, Vogelbaum, Michael, Sulman, Erik, Won, Minhee, Zhang, Peixin, Moazami, Golnaz, Macsai, Marian, Gilbert, Mark, Bain, Earle, Blot, Vincent, Ansell, Peter, Samanta, Suvajit, Kundu, Madan, Seidel, Clemens, De Vos, Filip, Hsu, Sigmund, Cardona, Andrés, Lombardi, Giuseppe, Bentsion, Dmitry, Peterson, Richard, Gedye, Craig, Lebrun-Frénay, Christine, Wick, Antje, Curran, Walter, Mehta, Minesh
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2019
נושאים:
Adult Clinical Trials - Non-Immunologic
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847524/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.064
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים